Trial Profile
A trial to assess preoperative liposome-encapsulated doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab in patients with HER2-positive breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2015
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Doxorubicin liposomal
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 07 Apr 2015 New trial record